

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
COELIAC DISEASE	
Total distributed	53
Total submitted	53
Reference	DQA1*03:03, *05:01, DQB1*02:01, *03:01
Number acceptable	46
Number unacceptable	3
Assessed	0

Lab Results for assessment	Alleles of Interest	Interpretative comments	Comments	Received	Tested	Assessment
11 HLA DQ2 Positive	DQB1*02:03:02	The presence of HLA-DQ2 is associated with, but not diagnostic for, coeliac disease. HLA DQ2 is present in about 21% of caucasians in the normal population		09/04/2019	16/04/2019	Acceptable
12 DQ2: Positive, DQ8: Negative, DQA1*05: Positive	DQ2, DQ8, DQA1*05	This genotype is associated with genetic susceptibility for coeliac disease.		10/04/2019	12/04/2019	Acceptable
15 Not Tested				0000-00-00	0000-00-00	Not assessed
17 DQA1*05:01 DQB1*02:01 (cis) - DQ2 Positive	DQA1*05:01 DQB1*02:01 (cis)	The major association for Coeliac disease involves the haplotype: DQA1*05:01 &e DQB1*02:01 (DQ2) and a minority of cases with the haplotype: DQA1*03:01 &e DQB1*03:02 (DQ8). (Nature Reviews Immunology 2002;2:647)		11/04/2019	12/04/2019	Acceptable
DQA1*05:05 02:01 DQB1*03:01 02:02 (trans) - N/A	DQA1*05:05 02:01 DQB1*03:01 02:02 (trans)					
DQA1*03:01 DQB1*03:02 - DQ8 Negative	DQA1*03:01 DQB1*03:02	This patient is POSITIVE for the DQA1*05:01-DQB1*02:01 (DQ2) haplotype and has a high genetic risk of having or developing coeliac disease.				
24 DQB1*02:01/05/07/08/09/53Q, *03:01/19/21/22/24/84N; DQA1*03:02/03/04, *05:01	DQB1*02, DQA1*05, DQB1*03:02	The patient possesses the following HLA alleles that are associated with Coeliac Disease: DQA1*05 and DQB1*02. Patients with this genotype have a high risk of predisposition to Coeliac Disease, however; presence of these alleles alone does not confirm diagnoses. Other clinical indications are required for diagnosis.		10/04/2019	15/04/2019	Acceptable
25 DQB1*02:01, *03:01; DQA1*03:02/03; *05:01	DQ2 DQ8	This patient is DQ2.5 positive, heterozygous. This patient is DQ2 positive which is associated with Coeliac Disease.		10/04/2019	18/04/2019	Acceptable
38 DQB1*02:01, *03:01 DQA1*03:03, 05:01	DQB1*02 and DQB1*03:02	This individual carries the DQA1*05:01, DQB1*02:01 (HLA-DQ2) variant associated with coeliac disease (high risk).		10/04/2019	18/04/2019	Acceptable
42 DQA1*03:02/03/04 DQA1*05:01 DQB1*02:01/02:05/02:07/02:08/02:09/02:14/02:27/02:48/02:53Q/02:59/02:63/02:79/02:82/02:83/02:96N/02:98/02:99/02:102/02:105/02:106 DQB1*03:01/03:19/03:21/03:22/03:24/03:27/03:28/03:29/03:35/03:42/03:44/03:46/03:47/03:48/03:49/03:50/03:51/03:52/03:53/03:54/03:55/03:57/03:59/03:71/03:77/03:82/03:83/03:84N/03:93/03:94/03:101/03:102/03:108/03:109/03:115/03:116/03:119/03:120/03:122/03:127/03:129/03:131/03:134/03:143/03:144/03:150/03:154/03:157/03:158/03:159/03:160/03:164/03:165/03:167/03:169/03:171/03:173/03:182/03:188/03:191/03:196/03:197/03:198/03:206/03:208/03:216/03:218/03:219/03:231/03:236/03:241/03:242/03:243/03:246/03:253/03:254/03:255/03:256/03:260/03:264/03:266/03:268/03:275/03:276N/03:281	HLA-DQ	This patient is POSITIVE for HLA-DQ2 (DQA1*05, DQB1*02) and NEGATIVE for HLA-DQ8 (DQB1*03:02). Patients with this genotype have a HIGH RISK of predisposition to Coeliac disease though other factors are likely involved	11/04/2019	12/04/2019	Acceptable	
78 Not tested				10/04/2019	0000-00-00	Not assessed
85 DQA1*05 Positive	DQA1*05	This individual has one of the HLA-DQ variants associated with coeliac disease. More than 97% of coeliac disease patients carry either HLA-DQ2 or DQ8. However, these variants are also present in approximately 40% of the general population and therefore whilst possession of the variant can support a diagnosis of coeliac disease it is not per se diagnostic of the condition.		10/04/2019	23/04/2019	Acceptable
DQB1*02 Positive	DQB1*02					
DQB1*03:02 negative	DQB1*03:02					
86 Coeliac disease-associated HLA alleles present: DQB1*02:01 DQA1*05:01 HLA DQ2: PRESENT - HLA-DQ2.5 HLA DQ8: ABSENT	DQ2 and DQ8 associated DQB1* and DQA1*	HLA-DQ2.5, which is associated with high genetic susceptibility for coeliac disease (CD), was detected in heterozygous form in this patient. As 25-30% of the general population has one of the CD-associated HLA alleles encoding DQ2 and/or DQ8 and only 3% of these individuals develop coeliac disease, identification of a CD-associated HLA allele is not diagnostic of CD. The presence of DQ2 and/or DQ8 increases the likelihood that the patient has CD but a diagnosis must be based on clinical findings, serum antibody detection tests and/or intestinal biopsy.		10/04/2019	23/04/2019	Acceptable
87 HLA-DQ2.5 positive heterozygous, P subunit HLA-DQ2.2/DQ2.5 positive heterozygous, rest negative	HLA-DQ2.2, HLA-DQ2.5, HLA-DQ8 and P subunit HLA-DQ2.2/DQ2.5	90-95% of Coeliac patients are HLA DQ2 or DQ8 positive (Husby S, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54:13660).		10/04/2019	12/04/2019	Acceptable
109 DQA1*05: positive DQB1*02:01 / DQB1*02:02: positive DQB1*03:02 (DQ8): negative	DQA1*05 DQB1*02:01 / DQB1*02:02 DQB1*03:02 (DQ8)	There is an HLA-associated risk for coeliac disease.		10/04/2019	16/04/2019	Acceptable
113 DQA1*03/DQB1*03:01 and DQA1*05:01/DQB1*02:01	DQ2 and DQ8	Presence of DQ2 associated with high risk of coeliac disease.		09/04/2019	17/04/2019	Acceptable
123 Not Tested				0000-00-00	0000-00-00	Not assessed
124 Not Tested				0000-00-00	0000-00-00	Not assessed
126 DQA1*05=POS, DQB1*02=NEG, DQA1*02=NEG, DQA1*03=POS, DQB1*03:02=NEG	DQA1*05, DQB1*02, DQA1*02, DQA1*03, DQB1*03:02	Increased risk for coeliac disease Pr&Absence des all&les HLA-DQB1*02 (DQ2) et DQA1*05 et absence de l&e all&le HLA-DQB1*03:02 (DQ8). Risque &e de pr&disposition & la maladie c&liaque.		10/04/2019	15/04/2019	Unacceptable
127 HLA-DQ2* positive, HLA-DQ8* negative	HLA-DQA1* HLA-DQB1* DQB1*02, *03:02; DQA1*05 HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*03:02 (DQ8)			11/04/2019	16/04/2019	Acceptable
129 DQB1*02 present, DQA1*05 present.	DQ2: DQB1*02:01-DQA1*05:01 DQ8: DQB1*03:02-DQA1*03:01	Presence of allele DQB1*02:01-DQA1*05:01		17/04/2019	18/04/2019	Unacceptable
142 HLA-DQA1*05 present	HLA-DQA1*05			22/04/2019	29/04/2019	Acceptable
HLA-DQB1*02 present	HLA-DQB1*02			11/04/2019	22/04/2019	Acceptable
HLA-DQB1*03:02 (DQ8) absent	HLA-DQB1*03:02 (DQ8) absent					
150 DQB1*02:01,03:01-DQA1*03:02,05:01	DQ2: DQB1*02:01-DQA1*03:01 DQ8: DQB1*03:02-DQA1*03:01					
154 HLA-DQA1*03:03,*05:01; HLA-DQB1*02:01,*03:01	HLA-DQA1*03:03,*05:01; HLA-DQB1*02:01,*03:01 HLA-DQ2 is coded by DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 ; HLA-DQ8 is coded by DQA1*03:01, DQB1*03:02	haplotype DQA1*05:01, DQB1*02:01 : Presence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 : absence haplotype DQA1*03:01, DQB1*03:02 : absence		10/04/2019	17/04/2019	Acceptable
		The patient has a susceptibility gene to coeliac disease (haplotype encoding HLA-DQ2). >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.				

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

159	DQA1*03 positive, DQA1*05 positive, DQB1*02 positive and DQB1*03:02 negative	DQA1*03, DQA1*05, DQB1*02 and DQB1*03:02	Presence of susceptibility phenotype for coeliac disease	11/04/2019	18/04/2019	Acceptable
173	DQA1*05 POSITIVE DQB1*02 POSITIVE DQA1*03 POSITIVE DQB1*03:02 NEGATIVE DQB1*03:03 NEGATIVE	HLA-DQA1*05, HLA-DQA1*03, HLA-DQB1*02, HLA-DQB1*03:02, HLA-DQB1*03:03	DQ2 POSITIVE	17/04/2019	23/04/2019	Acceptable
176	DQA1*05-Pos DQB1*02-Pos DQB1*03:02-Neg	DQA1*05 DQB1*02 DQB1*03:02	Celiac tissue type examination: Positive for HLA-DQB1 * 02 (DQ2), HLA-DQA1 * 05 and negative for HLA-DQB1 * 03: 02 (DQ8). The genetic risk of Celiac disease is present.	15/04/2019	16/04/2019	Acceptable
201	DQA1*03:02:03:03/03/04 DQA1*05:01 DQB1*02:01 DQB1*03:01			10/04/2019	17/04/2019	Acceptable
219	DQB1*03:02: negative DQA1*05: positive DQB1*02: positive DQA1*02: negative Reported serotype: DQ2.5	HLA-DQB1*03:02, HLA-DQA1*05, HLA-DQB1*02, HLA-DQA1*02	English translation: "HLA-DQ2.5 is detected in the form of HLA-DQB1*02 and HLA-DQA1*05. Most coeliac patients have these alleles. The alleles are common in the general population. Positive test alone is not sufficient to diagnose coeliac disease, but makes the diagnosis more probable."	24/04/2019	30/04/2019	Acceptable
223	DQA1*02 negative, DQA1*03 positive, DQA1*05 positive, DQB1*02 positive, DQB1*03:02 DQA1*02, DQA1*03, DQA1*05, DQB1*02, DQB1*03:02 negative			10/04/2019	16/04/2019	Acceptable
224	DQA1*05=POS, DQB1*02=POS, DQB1*03:02 group (DQ8)=NEG	DQA1*02, DQA1*03, DQA1*05 DQB1*02, DQB1*03:02	The patient is HLADQ2.5-positive. Coeliac disease is associated with this HLA-type in 90%.	15/04/2019	17/04/2019	Acceptable
225	DQ2-positive, DQ8-negative			10/04/2019	17/04/2019	Acceptable
245	DQB1*02,*03(serological equivalent DQ7); DQA1*03,*05	DQB1*02=DQA1*05 DQB1*02 DQB1*03:02	Presence of identified HLA-DQ specificities associated with a high risk of developing coeliac disease, higher than that of the general population. This result is in favor of coeliac disease only if it is associated with the clinical, biological and/or endoscopic signs corresponding to the diagnostic criteria.	10/04/2019	17/04/2019	Acceptable
255	DQA1*05 pos and DQB1*02 pos	DQA1*05, DQB1*02, DQB1*0302	DQ2.5 pos DQ8 neg The search for HLA-DQ2 (DQA1*05 - DQB1*02) was positive, compatible with coeliac disease. The HLA-DQB1*02 allele is present in heterozygosity.	10/04/2019	23/04/2019	Acceptable
263	DQA1*0201 absent, DQA1*03 present, DQA1*05 present DQB1*02 present (heterozygous), DQB1*0302 absent	HLA-DQA1*0201, DQA1*03, DQA1*05 HLA-DQB1*02, DQB1*0302 Homozygous or heterozygous status for DQB1*02 only		18/04/2019	23/04/2019	Acceptable
269	DQ2.5 positive	HLA DQ2.2 HLA DQ2.5 HLA DQ8	HLA DQ2.2 negative HLA DQ2.5 positive, heterozygous HLA DQ8 negative	07/04/2019	17/04/2019	Acceptable
274	HLADQ2cis (detected: DQA1*05, DQB1*02, DRB1*03)	HLADQ2cis, HLADQ2trans, HLA DQ2trans hp1, HLADQ2trans hp2, HLA DQ8		12/04/2019	15/04/2019	Acceptable
276	DQA1*05 positive, DQB1*02 positive, DQB1*03:02 negative	DQA1*05 DQB1*02 DQB1*03:02		10/04/2019	23/04/2019	Acceptable
278	Positive for genotype HLA-DQ2.5	DQA1*02, DQA1*02/*0301, DQA1*03, DQA1*0302/03, DQA1*05, DQB1*02, DQB1*02	The genotype indicates a risk of developing coeliac disease	15/04/2019	25/04/2019	Acceptable
279	Not Tested					
281	Positive association with coeliac disease. DQA1*05:01-DQB1*02:01 type.	DQA1* DQB1* DQA1*02 DQA1*05 DQA1*03 DQB1*02 DQB1*03:02	Presence of the HLA-DQ2 (DQA1*05, DQB1*02) heterodimer. Absent DQB1*02 homozygosity.	0000-00-00 09/04/2019	0000-00-00 16/04/2019	Not assessed Acceptable
307	DQA1*03,*05:01 DQB1*02,*03			10/04/2019	12/04/2019	Acceptable
315	POSITIVE (DQB1*02, DQB1*03:01)	DQB1*02, DQB1*03:02		10/04/2019	16/04/2019	Acceptable
317	Positive for alleles: DQA1x03, DQA1x0302/03, DQA1x05, DQB1x02, DQB1x02/x0302	HLA DQA1 and HLA DQB1	Positive for HLA DQ 2.5	15/04/2019	17/04/2019	Unacceptable
319	DQ2 Pos DQ8 Neg	DQA1*05 Pos DQB1*02 Pos DQB1*0302 Neg DQB1*02:01, DQB1*03:02		10/04/2019	12/04/2019	Acceptable
331	DQB1*02:01, DQB1*03:01/03:13	DQA1*05, DQA1*02, DQA1*03, DQB1*02, DQB1*0301, DQB1*0302, DRB1*03, DRB1*11, DRB1*12, DRB1*07, DRB1*04		12/04/2019	24/04/2019	Acceptable
333	DQA1*05, DQB1*02, DRB1*03, DQB1*0301, DQA1*03, DRB1*04			15/04/2019	18/04/2019	Acceptable
338	DQB1*02:01,*03:01; DQA1*03:03,*05:01; DRB1*03,*04	HLA-DQB1, DQA1, DRB1*03,*04,*07,*11	Presence of DQB1*02:01 ; absence of DQB1*03:02. Coeliac disease predisposing HLA-DQ type in heterozygous state. The heterodimer DQ2 (DQA1*05, DQB1*02) presence is indicative of susceptibility to Coeliac disease but it does not imply the development of the disease whose diagnosis must be verified by clinical methods. The specific coeliac disease risk varies depending on different haplotype combinations and might also depend on ethnicity and other factors. * The presence of positive mix 16 only did not allow a clear HLA-DQA1*03 typing and it was necessary to use Olerup DQA1 high resolution SSP kit. (DQA1*03:03:01)	11/04/2019	28/05/2019	Acceptable
339	Found DQA105 positive and DQB102 positive, therefore genotype: DQ2	DQA105, DQB102 and DQB10302		10/04/2019	16/04/2019	Acceptable
346	HLA-DQA1*05-POS, HLA-DQB1*02-POS, HLA-DQB1*03:02P (DQ8)-NEG	DQA1*05, DQB1*02, DQB1*03:02P (DQ8)		15/04/2019	23/04/2019	Acceptable
347	HLA-DQ2.5-positive, HLA-DQ2.2-negative, HLA-DQ8-negative	HLA-DQA1 / HLA-DQB1	Increased risk for the development of Coeliac Disease: determination of serological parameters or biopsy from the small intestine recommended.	16/04/2019	17/04/2019	Acceptable
355	HLA-DQ2.5 positive		The patient has a genetic disposition to develop coeliac disease. Analyzing for coeliac antibodies in plasma is recommended.	10/04/2019	30/04/2019	Acceptable
359	Alleles positive: DQA1*03, DQA1*05, DQA1*03:02/03, DQB1*02, DQB1*03*06, alpha-subunit HLA-DQ2.5, alpha-subunit HLA-DQ8, beta-subunit HLA-DQ2.2/DQ2.5	DQA1*02, DQA1*03, DQA1*05, DQA1*01/*04/*06, DQA1*02/*03:01, DQA1*03:02/03, DQB1*02, DQB1*03:02, DQB1*03*06, DQB1*04*05, alpha-subunit HLA-DQ2.2, alpha-subunit HLA-DQ2.5, alpha-subunit HLA-DQ8, beta-subunit HLA-DQ2.2/DQ2.5, beta-subunit HLA-DQ8	HLA-DQ2.5: positive, heterozygous beta-subunit HLA-DQ2.2/DQ2.5 : positive heterozygous	11/04/2019	17/04/2019	Acceptable
363	HLA DQ2.2 = Absent ; HLA DQ2.5 = Present ; HLA DQ8 = Absent	DQA1*02, DQA1*02/*0301; DQA1*03; DQA1*0302/03; DQA1*05; DQB1*02; DQB1*02*03:02		09/04/2019	16/04/2019	Acceptable
413	DQ2 present (DQA1*05:01,*03; DQB1*02:01,*03:01; DRB1*03,*04)	DQ2; DQ8 based on the results of DQA1*05:01; DQA1*05:05; DQA1*02:01; DQA1*03; DQB1*02:02; DQB1*02:01; DQB1*03:02; DRB1*11		10/04/2019	15/04/2019	Acceptable
1350	DQ2.5 (DQ2 cis)	detected alleles (allelic groups): HLA-DQ2 cis (DQ2.5): DQA1*05-DQB1*02-DRB1*03 HLA-DQ2 trans (DQ2.5): DQA1*05-DQB1*03:01-DRB1*11/DRB1*12 DQA1*02-DQB1*02-DRB1*07 HLA-DQ2 trans haplotype (Hp1) carrier: DQA1*05-DQB1*03:01-DRB1*11/DRB1*12 HLA-DQ2 trans haplotype (Hp2) carrier: (DQ2.2): DQA1*02-DQB1*02-DRB1*07 DQ8:DQA1*03-DQB1*03:02-DRB1*04	detected HLA genotype is associated with the risk of coeliac disease	10/04/2019	16/04/2019	Acceptable

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
NARCOLEPSY	21
Total distributed	21
Total submitted	21
Reference	DOB1*02:01, *03:01
Number acceptable	21
Number unaccepted	-
Assessed	<input checked="" type="checkbox"/>

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11 DOB1*06:02 Negative	DOB1*06:02	HLA-DQB1 allele known to be associated with Narcolepsy is not present		09/04/2019	16/04/2019	Acceptable
12				10/04/2019	12/04/2019	Not assessed
15 Not Tested				0000-00-00	0000-00-00	Not assessed
17 DOB1*06:02 - Negative	DOB1*06:02	This patient is NEGATIVE for the narcolepsy associated allele DOB1*06:02.		11/04/2019	12/04/2019	Acceptable
24 DOB1*02:01/05/07/08/09/53Q, *03:01/19/21/22/24/84N; DQA1*03:02/03/04, *05:01	DOB1*06:02	HLA-DQB1*06:02 is associated with narcolepsy-cataplexy. This patient is NEGATIVE for HLA-DQB1*06:02.		10/04/2019	15/04/2019	Acceptable
25 DOB1*06:02 negative	DOB1*06:02			10/04/2019	18/04/2019	Acceptable
38 DOB1*02:01, *03:01	DOB1*06:02	The patient does not carry the associated HLA alleles which confer susceptibility to Narcolepsy		10/04/2019	18/04/2019	Acceptable
42 DOB1*02:01:02:05:02:07:02:08:02:09:02:14:02:27:02:48:02:53Q/02:59:02:63:02:79/02HLA-DQB1*06:02 :82:02:83:02:96N/02:98:02:99:02:102:02:105:02:106		This patient is HLA-DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DOB1*06:02.		11/04/2019	12/04/2019	Acceptable
DOB1*03:01/03:19/03:21/03:22/03:24/03:27/03:28/03:29/03:35/03:42/03:44/03:46/03:47/03:48/03:49/03:50/03:51/03:52/03:53/03:54/03:56/03:57/03:59/03:71/03:77/03:82/03:83/03:84N/03:93/03:94/03:101/03:102/03:108/03:109/03:115/03:116/03:119/03:120/03:122/03:127/03:129/03:131/03:134/03:143/03:144/03:150/03:154/03:157/03:158/03:159/03:160/03:164/03:165/03:167/03:169/03:171/03:173/03:182/03:188/03:191/03:196/03:197/03:198/03:206/03:208/03:216/03:218/03:219/03:231/03:236/03:241/03:242/03:243/03:246/03:253/03:254/03:255/03:256/03:260/03:264/03:266/03:268/03:275/03:276N/03:281				10/04/2019	0000-00-00	Not assessed
78				10/04/2019	23/04/2019	Not assessed
85				10/04/2019	23/04/2019	Not assessed
86				10/04/2019	23/04/2019	Not assessed
87				10/04/2019	12/04/2019	Not assessed
109 DQA1*01:02: negative	DQA1*01:02	There is no HLA-associated risk for narcolepsy disease.		10/04/2019	16/04/2019	Acceptable
DOB1*06:02: negative	DOB1*06:02			10/04/2019	16/04/2019	Acceptable
113 DOB1*02, 03	DOB1*06:02	The patient does not carry the associated allele which confers susceptibility to narcolepsy (HLA-DQB1*06:02)		09/04/2019	17/04/2019	Acceptable
123				0000-00-00	0000-00-00	Not assessed
124				0000-00-00	0000-00-00	Not assessed
126				10/04/2019	15/04/2019	Not assessed
127 HLA-DQB1*06:02 negative	HLA-DQB1*06:02			11/04/2019	16/04/2019	Acceptable
129 DOB1*06:02 negative	DOB1*06:02	Risk of narcolepsy not increased		22/04/2019	29/04/2019	Acceptable
142 HLA-DQB1*06:02 absent	HLA-DQB1*06:02			11/04/2019	22/04/2019	Acceptable
150 DOB1*02:01:03:01	DOB1*06:02	Absence of allele DOB1*06:02.		17/04/2019	18/04/2019	Acceptable
154 HLA-DQB1*02:01,*03:01	HLA-DQB1*06:02	Allele DOB1*06:02 : absence		10/04/2019	17/04/2019	Acceptable
		The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.				
159 DOB1*06:02 negative, DQA1*01:02 negative	DOB1*06:02, DQA1*01:02	Absence of susceptibility phenotype for narcolepsy		11/04/2019	18/04/2019	Not assessed
173				17/04/2019	23/04/2019	Not assessed
176				15/04/2019	16/04/2019	Not assessed
201				10/04/2019	17/04/2019	Not assessed
219				24/04/2019	30/04/2019	Not assessed
223 DQA1*01:02: negative, DOB1*06:02: negative	DQA1*01:02, DOB1*06:02			10/04/2019	16/04/2019	Acceptable
224 DQA1*01:02=NEG, DOB1*06:02=NEG	DQA1*01:02, DOB1*06:02			10/04/2019	17/04/2019	Acceptable
225 DOB1*06:02:negative	DOB1*06:02	The patient don't have the HLA-type associated with narcolepsy.		15/04/2019	17/04/2019	Acceptable
245 DOB1*02,*03(serological equivalent DQ7)	DOB1*06:02	Absence of the susceptibility allele for narcolepsy-cataplexy DOB1*06:02. This allele is present in 12 to 38% of the general population, in 40 to 60% of patients with narcolepsy without cataplexy and in 18% of patients with idiopathic hypersomnia. This result makes the diagnosis of narcolepsy-cataplexy unlikely but does not exclude the diagnosis.		10/04/2019	17/04/2019	Acceptable
255				10/04/2019	23/04/2019	Not assessed
263				18/04/2019	23/04/2019	Not assessed
269				07/04/2019	17/04/2019	Not assessed
274				12/04/2019	15/04/2019	Not assessed
276 DOB1*06:02 negative	DOB1*06:02			10/04/2019	23/04/2019	Acceptable
278				15/04/2019	25/04/2019	Not assessed
279				0000-00-00	0000-00-00	Not assessed
281 no known association with narcolepsia.	DOB1*			09/04/2019	16/04/2019	Acceptable
307				10/04/2019	12/04/2019	Not assessed
315 NEGATIVE (DOB1*02, DOB1*03:01)	DOB1*06:02			10/04/2019	16/04/2019	Acceptable
317				15/04/2019	17/04/2019	Not assessed
319				10/04/2019	12/04/2019	Not assessed
331 DOB1*02:01, DOB1*03:01/03:13	DOB1*06:02	Absence of DOB1*06:02		12/04/2019	24/04/2019	Acceptable
333				15/04/2019	18/04/2019	Not assessed
338				11/04/2019	28/05/2019	Not assessed
339				10/04/2019	16/04/2019	Not assessed
346				16/04/2019	23/04/2019	Not assessed
347				16/04/2019	17/04/2019	Not assessed
355				10/04/2019	30/04/2019	Not assessed
359				11/04/2019	17/04/2019	Not assessed
363				09/04/2019	16/04/2019	Not assessed
413				10/04/2019	15/04/2019	Not assessed
1350				10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

8/3/2019	Results for assessment
ACTINIC PRURIGO	3
Total distributed	3
Total submitted	3
Reference	DRB1*03:01, *04:07
Number acceptable	3
Number unacceptable	-
Assessed <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11							
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25	DRB1*04:07 positive	DRB1*04:07	This patient is Positive for HLA DRB1*04:07 allele which is associated with Actinic Prurigo.		10/04/2019	18/04/2019	Acceptable
38	DRB1*03:01, 04:07	DRB1*04:07	This patient carries DRB1*04:07 which confers susceptibility to Actinic Prurigo		10/04/2019	18/04/2019	Acceptable
42	DRB1*03:01/03:06/03:13/03:28/03:37/03:45/03:46/03:47/03:48/03:50/03:51/03:55/03:5HLA-DRB1*04:07 6/03:58/03:59/03:61/03:62/03:67N/03:68N/03:72/03:73/03:80/03:82/03:83/03:98/03:10 0/03:104/03:106/03:107/03:109/03:110/03:114/03:116/03:117/03:121/03:123/03:124/0 3:127/03:129/03:132/03:134/03:136/03:137/03:138/03:139/03:142/03:143/03:144/03:1 46		This patient is HLA-DRB1*04:07 POSITIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07		10/04/2019 11/04/2019	18/04/2019 12/04/2019	Acceptable Acceptable
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113					09/04/2019	17/04/2019	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	18/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245	Not Tested	NT	NT		10/04/2019	17/04/2019	Not assessed
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
BIRDSHOT RETINOPATHY	
Total distributed	7
Total submitted	7
Reference	A*01, *68
Number acceptable	7
Number unacceptable	-
Assessed	<input checked="" type="checkbox"/>

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11 HLA-A29 Negative	A*29	HLA-A allele known to be associated with but not diagnostic for birdshot chorioretinopathy is absent		09/04/2019	16/04/2019	Acceptable
12				10/04/2019	12/04/2019	Not assessed
15 Not Tested				0000-00-00	0000-00-00	Not assessed
17				11/04/2019	12/04/2019	Not assessed
24				10/04/2019	15/04/2019	Not assessed
25 A*29 negative	A*29	Patient is Negative for HLA A29 antigen which is associated with Birdshot Retinopathy.		10/04/2019	18/04/2019	Acceptable
38 A*01, *68	A*29	This patient does not carry HLA-A*29 which confers susceptibility to Birdshot Retinopathy		10/04/2019	18/04/2019	Acceptable
42 A*01:01/01:01L/01:01N/01:03/01:04N/01:09/01:11N/01:18N/01:22N/01:23/01:24/01:29HLA-A*29/01:32/01:33/01:35/01:36/01:37/01:38/01:39/01:40/01:42/01:43/01:44/01:45/01:47/01:48/01:50/01:52N/01:53N/01:54/01:55/01:56N/01:57N/01:58/01:59/01:62/01:65/01:67/01:70/01:74/01:75/01:76/01:77/01:78/01:79/01:80/01:81/01:82/01:84/01:86/01:87N/01:88/01:90/01:91/01:92/01:93/01:94/01:96/01:97/01:100/01:101/01:103/01:105/01:106/01:107/01:109/01:110/01:111/01:112/01:113/01:115/01:116/01:117/01:118/01:120/01:121/01:122/01:123N/01:124/01:125/01:129/01:131/01:132/01:135/01:137/01:138/01:139/01:140/01:141/01:142/01:143/01:144/01:145/01:146/01:148/01:150/01:151/01:152/01:153/01:154/01:155/01:156/01:157/01:158/01:161/01:164/01:165/01:166/01:171/01:172/01:174/01:175/01:177/01:179N/01:180/01:181/01:182/01:183/01:184/01:185/01:186N/01:187/01:189/01:191/01:193/01:195/01:197/01:198/01:199/01:201/01:202/01:203/01:206/01:207/01:210/01:212/01:213/01:216/01:217/01:218/01:219/01:220/01:221/01:222/01:223/01:224/01:225/01:226/01:227/01:228Q/01:230/01:231/01:232/01:234/01:235/01:237/01:239/01:240N/01:241/01:242/01:245/01:246/01:247N/01:248Q/01:249/01:251/01:252/01:253/01:254/01:257/01:258N/01:259/01:260/01:261A*68:01/68:21/68:25/68:29/68:43/68:55/68:56/68:58/68:59N/68:68/68:71/68:72/68:76/68:79/68:87/68:88/68:94N/68:103/68:106/68:119/68:139/68:143/68:154/68:155/68:161/68:165/68:166/68:175/68:176/68:177	This patient is HLA-A*29 NEGATIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.	11/04/2019	12/04/2019	Acceptable		
78				10/04/2019	0000-00-00	Not assessed
85				10/04/2019	23/04/2019	Not assessed
86				10/04/2019	23/04/2019	Not assessed
87				10/04/2019	12/04/2019	Not assessed
109				10/04/2019	16/04/2019	Not assessed
113				09/04/2019	17/04/2019	Not assessed
123				0000-00-00	0000-00-00	Not assessed
124				0000-00-00	0000-00-00	Not assessed
126				10/04/2019	15/04/2019	Not assessed
127				11/04/2019	16/04/2019	Not assessed
129				22/04/2019	29/04/2019	Not assessed
142				11/04/2019	22/04/2019	Not assessed
150 A*01.68.	A*29	Absence of allele A*29.		17/04/2019	18/04/2019	Acceptable
154				10/04/2019	17/04/2019	Not assessed
159				11/04/2019	16/04/2019	Not assessed
173				17/04/2019	23/04/2019	Not assessed
176				15/04/2019	16/04/2019	Not assessed
201				10/04/2019	17/04/2019	Not assessed
219				24/04/2019	30/04/2019	Not assessed
223				10/04/2019	16/04/2019	Not assessed
224				10/04/2019	17/04/2019	Not assessed
225				15/04/2019	17/04/2019	Not assessed
245 A*01,*68	A*29	Absence of susceptibility allele A*29. In case of clinical signs of posterior uveitis, the absence of the HLA-A*29 allele is very little in favor of the diagnosis of birdshot disease. The prevalence of HLA-A*29 in birdshot patients is 90 to 100% according to published studies.		10/04/2019	17/04/2019	Acceptable
255				10/04/2019	23/04/2019	Not assessed
263				18/04/2019	23/04/2019	Not assessed
269				07/04/2019	17/04/2019	Not assessed
274				12/04/2019	15/04/2019	Not assessed
276				10/04/2019	23/04/2019	Not assessed
278				15/04/2019	25/04/2019	Not assessed
279				0000-00-00	0000-00-00	Not assessed
281				09/04/2019	16/04/2019	Not assessed
307				10/04/2019	12/04/2019	Not assessed
315 NEGATIVE (A*1, A*68)	A*29			10/04/2019	16/04/2019	Acceptable
317				15/04/2019	17/04/2019	Not assessed
319				10/04/2019	12/04/2019	Not assessed
331				12/04/2019	24/04/2019	Not assessed
333				15/04/2019	18/04/2019	Not assessed
338				11/04/2019	28/05/2019	Not assessed
339				10/04/2019	16/04/2019	Not assessed
346				16/04/2019	23/04/2019	Not assessed
347				16/04/2019	17/04/2019	Not assessed
355				10/04/2019	30/04/2019	Not assessed
359				11/04/2019	17/04/2019	Not assessed
363				09/04/2019	16/04/2019	Not assessed
413				10/04/2019	15/04/2019	Not assessed
1350				10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
BEHCET'S DISEASE	12
Total distributed	12
Total submitted	B*08, *51
Reference	10
Number acceptable	-
Number unacceptable	-
Assessed %	100

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11 HLA-B*51(5) Positive	B*51	HLA-B*51(5) is associated with but is not diagnostic for Behcet's disease.		09/04/2019	16/04/2019	Acceptable
12 HLA B*51: Positive	HLA B*51	This patient is positive for HLA-B*51 (the HLA specificity associated with Behcet's disease).		10/04/2019	12/04/2019	Acceptable
15 Not Tested		HLA-B*51 is present in approximately 9% of the normal Caucasian population.				
17				0000-00-00	0000-00-00	Not assessed
24				11/04/2019	12/04/2019	Not assessed
25 B*51 Positive	B*51	The HLA B51 antigen associated with Behcet's Disease is present. The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.		10/04/2019	15/04/2019	Not assessed
				10/04/2019	18/04/2019	Acceptable
38 HLA-B*08, *51	B*51	This patient carries HLA-B*51 which confers susceptibility to Behcet's disease.		10/04/2019	18/04/2019	Acceptable
42 B*08:01/08:05/08:08N/08:10/08:18/08:19N/08:22/08:24/08:26/08:27/08:30N/08:39/08:41/08:44/08:45/08:46/08:50/08:51/08:53/08:57/08:59/08:61/08:63/08:64/08:66/08:67N/08:71/08:72N/08:73/08:75/08:77/08:80/08:81/08:83/08:85/08:86N/08:88/08:90/08:91/08:93/08:95/08:97/08:98/08:99/08:100/08:102/08:104/08:105/08:106/08:109/08:114/08:119/08:120/08:121/08:122/08:124/08:127/08:128/08:137/08:138/08:140/08:141/08:142/08:144/08:145/08:147/08:148N/08:149/08:150/08:151/08:158/08:159/08:160/08:161/08:162/08:163/08:164/08:166/08:168/08:172/08:173/08:176/08:178/08:179/08:182/08:183/08:189/08:190/08:191/08:193/08:194/08:196	HLA-B*51	This patient is HLA-B*51 POSITIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.	11/04/2019	12/04/2019	Acceptable	
				11/04/2019	12/04/2019	Acceptable
78 Not tested				10/04/2019	0000-00-00	Not assessed
85				10/04/2019	23/04/2019	Not assessed
86				10/04/2019	23/04/2019	Not assessed
87				10/04/2019	12/04/2019	Not assessed
109				10/04/2019	16/04/2019	Not assessed
113 Haemolysis of the sample. No result available	B51			09/04/2019	17/04/2019	Not assessed
123				0000-00-00	0000-00-00	Not assessed
124				0000-00-00	0000-00-00	Not assessed
126				10/04/2019	15/04/2019	Not assessed
127				11/04/2019	16/04/2019	Not assessed
129				22/04/2019	29/04/2019	Not assessed
142 HLA-B*51 present	HLA-B*51			11/04/2019	22/04/2019	Acceptable
150 B*08:51:	B*51	Presence of allele B*51.		17/04/2019	18/04/2019	Acceptable
154				10/04/2019	17/04/2019	Not assessed
159				11/04/2019	18/04/2019	Not assessed
173 HLA-B*51 POSITIVE	HLA-B*51	High risk of Behet Syndrome		17/04/2019	23/04/2019	Acceptable
176				15/04/2019	16/04/2019	Not assessed
201				10/04/2019	17/04/2019	Not assessed
219				24/04/2019	30/04/2019	Not assessed
223				10/04/2019	16/04/2019	Not assessed
224				10/04/2019	17/04/2019	Not assessed
225				15/04/2019	17/04/2019	Not assessed
245 B*08,*51	B*51	Presence of the susceptibility allele HLA-B*51. The presence of this allele confers on the wearer a risk multiplied by 8 to develop a Behçet disease compared to the general population. 30-50% of affected patients have this allele. This result alone does not support the diagnosis of Behçet's disease. It must be associated with other clinico-biological signs corresponding to the diagnostic criteria.		10/04/2019	17/04/2019	Acceptable
255				10/04/2019	23/04/2019	Not assessed
263				18/04/2019	23/04/2019	Not assessed
269				07/04/2019	17/04/2019	Not assessed
274				12/04/2019	15/04/2019	Not assessed
276				10/04/2019	23/04/2019	Not assessed
278				15/04/2019	25/04/2019	Not assessed
279				0000-00-00	0000-00-00	Not assessed
281				09/04/2019	16/04/2019	Not assessed
307				10/04/2019	12/04/2019	Not assessed
315 POSITIVE (B*8, B*51)	B*51			10/04/2019	16/04/2019	Acceptable
317				15/04/2019	17/04/2019	Not assessed
319				10/04/2019	12/04/2019	Not assessed
331				12/04/2019	24/04/2019	Not assessed
333				15/04/2019	18/04/2019	Not assessed
338				11/04/2019	28/05/2019	Not assessed
339				10/04/2019	16/04/2019	Not assessed
346				16/04/2019	23/04/2019	Not assessed
347				16/04/2019	17/04/2019	Not assessed
355				10/04/2019	30/04/2019	Not assessed
359				11/04/2019	17/04/2019	Not assessed
363				09/04/2019	16/04/2019	Not assessed
413				10/04/2019	15/04/2019	Not assessed
1350				10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
RHEUMATOID ARTHRITIS	
Total distributed	2
Total submitted	2
Reference	DRB1*03:01, *04:07
Number acceptable	2
Number unacceptable	-
Assessed <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11				09/04/2019	16/04/2019	Not assessed
12				10/04/2019	12/04/2019	Not assessed
15				0000-00-00	0000-00-00	Not assessed
17				11/04/2019	12/04/2019	Not assessed
24				10/04/2019	15/04/2019	Not assessed
25				10/04/2019	18/04/2019	Not assessed
38				10/04/2019	18/04/2019	Not assessed
42				11/04/2019	12/04/2019	Not assessed
78				10/04/2019	0000-00-00	Not assessed
85				10/04/2019	23/04/2019	Not assessed
86				10/04/2019	23/04/2019	Not assessed
87				10/04/2019	12/04/2019	Not assessed
109				10/04/2019	16/04/2019	Not assessed
113 DRB1*03, 04:07	DRB1*01:01, DRB1*01:02, DRB1*04:01, DRB1*04:04, DRB1*04:05, DRB1*04:08, DRB1*04:09, DRB1*04:10, DRB1*10, DRB1*14:02, DRB1*14:06	Absence of any susceptibility allele for Rheumatoid Arthritis		09/04/2019	17/04/2019	Acceptable
123				0000-00-00	0000-00-00	Not assessed
124				0000-00-00	0000-00-00	Not assessed
126				10/04/2019	15/04/2019	Not assessed
127				11/04/2019	16/04/2019	Not assessed
129				22/04/2019	29/04/2019	Not assessed
142				11/04/2019	22/04/2019	Not assessed
150				17/04/2019	18/04/2019	Not assessed
154				10/04/2019	17/04/2019	Not assessed
159				11/04/2019	18/04/2019	Not assessed
173				17/04/2019	23/04/2019	Not assessed
176				15/04/2019	16/04/2019	Not assessed
201				10/04/2019	17/04/2019	Not assessed
219				24/04/2019	30/04/2019	Not assessed
223				10/04/2019	16/04/2019	Not assessed
224				10/04/2019	17/04/2019	Not assessed
225				15/04/2019	17/04/2019	Not assessed
245 DRB1*03,*04	DRB1*04:01,*04:04,*04:05,*04:08 DRB1*10 DRB1*01:01,*01:02,*01:04 DRB1*14:06	No single or double dose shared epitope. The patient has no shared epitopes associated with a risk of developing rheumatoid arthritis. 20% of patients with rheumatoid arthritis do not have a shared epitope, so this result does not eliminate the diagnosis.		10/04/2019	17/04/2019	Acceptable
255				10/04/2019	23/04/2019	Not assessed
263				18/04/2019	23/04/2019	Not assessed
269				07/04/2019	17/04/2019	Not assessed
274				12/04/2019	15/04/2019	Not assessed
276				10/04/2019	23/04/2019	Not assessed
278				15/04/2019	25/04/2019	Not assessed
279				0000-00-00	0000-00-00	Not assessed
281				09/04/2019	16/04/2019	Not assessed
307				10/04/2019	12/04/2019	Not assessed
315				10/04/2019	16/04/2019	Not assessed
317				15/04/2019	17/04/2019	Not assessed
319				10/04/2019	12/04/2019	Not assessed
331 DRB1*03, DRB1*04 or DRB1*04, DRB1*14	DRB1*04	Presence of DRB1*04		12/04/2019	24/04/2019	Not assessed
333				15/04/2019	18/04/2019	Not assessed
338				11/04/2019	28/05/2019	Not assessed
339				10/04/2019	16/04/2019	Not assessed
346				16/04/2019	23/04/2019	Not assessed
347				16/04/2019	17/04/2019	Not assessed
355				10/04/2019	30/04/2019	Not assessed
359				11/04/2019	17/04/2019	Not assessed
363				09/04/2019	16/04/2019	Not assessed
413				10/04/2019	15/04/2019	Not assessed
1350				10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
DIABETES	5
Total distributed	5
Total submitted	5
Reference	DRB1*03:01, *04:07, DQA1*03:03, *05:01, DQB1*02:01, *03:01
Number acceptable	4
Number unacceptable	1
Assessed <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11				09/04/2019	16/04/2019	Not assessed
12				10/04/2019	12/04/2019	Not assessed
15				0000-00-00	0000-00-00	Not assessed
17				11/04/2019	12/04/2019	Not assessed
24				10/04/2019	15/04/2019	Not assessed
25				10/04/2019	18/04/2019	Not assessed
38				10/04/2019	18/04/2019	Not assessed
42				11/04/2019	12/04/2019	Not assessed
78				10/04/2019	0000-00-00	Not assessed
85				10/04/2019	23/04/2019	Not assessed
86				10/04/2019	23/04/2019	Not assessed
87				10/04/2019	12/04/2019	Not assessed
109				10/04/2019	16/04/2019	Not assessed
113	DRB1*03:01/DQA1*05:01/DQB1*02:01 and DRB1*04:07/DQA1*03/DQB1*03:01	DRB1*04/DQA1*03:01/DQB1*03:02, DRB1*03:01/DQA1*05:01/DQB1*02:01	The patient expresses the HLA-DRB1*03:01/DQA1*05:01/DQB1*02:01 haplotype associated with type 1 diabetes.	09/04/2019	17/04/2019	Acceptable
123				0000-00-00	0000-00-00	Not assessed
124				0000-00-00	0000-00-00	Not assessed
126				10/04/2019	15/04/2019	Not assessed
127				11/04/2019	16/04/2019	Not assessed
129	DQB1*02, *03:01; DQA1*03, *05; DRB1*04:07	DQB1*02, *03:01, *03:02, DQB1*03:03, *03:04, *04, *05:01, *05:02, *05:03, *06:01, *06:02, *06:03, *06:04; DRB1*04:01, *04:02, .04:03/6, *04:04, *04:05, *04:07	Neutral genotype. A combination of risk and protection associated haplotypes	22/04/2019	29/04/2019	Acceptable
142				11/04/2019	22/04/2019	Not assessed
150	DRB1*03:07.	DR3 DRB1*03:01... DR4 DRB1*04:05...	Presence of allele DRB1*03:01.	17/04/2019	18/04/2019	Unacceptable
154	HLA-DRB1*03,*04; HLA-DQA1*03:03,*05:01; HLA-DQB1*02:01,*03:01	HLA-DRB1* is typed to the 2-digit level and HLA-DQA1* and HLA-DQB1* are typed to the 4-digit level to detect the following haplotypes : HLA-DRB1*03, DQA1*05:01, DQB1*02:01 and HLA-DRB1*04, DQA1*03:01, DQB1*03:02	haplotype DR3.DQ2 (DRB1*03.DQA1*05:01.DQB1*02:01) : Presence haplotype DR4.DQ8 (DRB1*04.DQA1*03:01.DQB1*03:02) : absence The patient expresses the HLA-DR3.DQ2 haplotype associated with type 1 diabetes. The DR3.DQ2 and DR4.DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.	10/04/2019	17/04/2019	Acceptable
159				11/04/2019	18/04/2019	Not assessed
173				17/04/2019	23/04/2019	Not assessed
176				15/04/2019	16/04/2019	Not assessed
201				10/04/2019	17/04/2019	Not assessed
219				24/04/2019	30/04/2019	Not assessed
223				10/04/2019	16/04/2019	Not assessed
224				10/04/2019	17/04/2019	Not assessed
225				15/04/2019	17/04/2019	Not assessed
245	DRB1*03(serological equivalent DR17),*04; DQA1*03,*05; DQB1*02,*03(serological equivalent DQ7)	Susceptible: DRB1*03:01.DQA1*05:01.DQB1*02:01 DRB1*04:01.DQA1*03:01.DQB1*03:02/04 DRB1*04:02.DQA1*03:01.DQB1*03:02/04 DRB1*04:04.DQA1*03:01.DQB1*03:02/04 DRB1*04:05.DQA1*03:01.DQB1*03:02/04 Protector: DRB1*15:01.DQA1*01:02.DQB1*06:02 DRB1*14:01.DQA1*01:01.DQB1*05:03 DRB1*07:01.DQA1*02:01.DQB1*03:03 DRB1*04:03.DQA1*03:01.DQB1*03:02	Presence of alleles that may constitute a susceptibility haplotype HLA-DRB1*03/DQA1*05/DQB1*02, giving the individual carrier an increased risk of developing type 1 diabetes, with an odds ratio of 3.64. This result is not a diagnostic criterion for the disease.	10/04/2019	17/04/2019	Acceptable
255				10/04/2019	23/04/2019	Not assessed
263				18/04/2019	23/04/2019	Not assessed
269				07/04/2019	17/04/2019	Not assessed
274				12/04/2019	15/04/2019	Not assessed
276				10/04/2019	23/04/2019	Not assessed
278				15/04/2019	25/04/2019	Not assessed
279				0000-00-00	0000-00-00	Not assessed
281				09/04/2019	16/04/2019	Not assessed
307				10/04/2019	12/04/2019	Not assessed
315				10/04/2019	16/04/2019	Not assessed
317				15/04/2019	17/04/2019	Not assessed
319				10/04/2019	12/04/2019	Not assessed
331	DRB1*03, DRB1*04 or DRB1*04, DRB1*14	DRB1*03, DRB1*04	Presence of DRB1*03 cannot be assessed ; Presence of DRB1*04	12/04/2019	24/04/2019	Not assessed
333				15/04/2019	18/04/2019	Not assessed
338				11/04/2019	28/03/2019	Not assessed
339				10/04/2019	16/04/2019	Not assessed
346				16/04/2019	23/04/2019	Not assessed
347				16/04/2019	17/04/2019	Not assessed
355				10/04/2019	30/04/2019	Not assessed
359				11/04/2019	17/04/2019	Not assessed
363				09/04/2019	16/04/2019	Not assessed
413				10/04/2019	15/04/2019	Not assessed
1350				10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

803/2019	Results for assessment
OTHER	0
Total distributed	0
Total submitted	0
Reference	-
Number acceptable	-
Number unacceptable	-
Assessed <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	12/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113					09/04/2019	17/04/2019	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	18/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245					10/04/2019	17/04/2019	Not assessed
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					15/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed